Medicare Part B Step Therapy Gonadotropin Releasing Hormone Agonists
Customize your policy alerts
Sign up for zing_health Policy 4257-D alerts
Get alerted when Policy 4257-D changes without checking for updates manually.
Monitor payer policy activity
Medicare Part B coverage of gonadotropin-releasing hormone agonists for prostate cancer; Eligard is preferred, and non-preferred products require a qualifying clinical exception through prior authorization.
No material clinical or coverage changes in this revision.
Non-Preferred Product Exceptions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.